同济大学学报（医学版）2018，Vol.39Issue(3)：1-6,6.DOI:10.16118/j.1008-0392.2018.03.001
血清hsa-miR-486-5p在乳腺癌早期诊断中的价值
Clinical value of serum hsa-miR-486-5p in detecting early-stage breast cancer
摘要
Abstract
Objective To assess the clinical value of serum microRNAs ( miRNAs ) in early diagnosis of breast cancer. Methods High-throughput sequencing was performed to obtain target miRNAs in tissue samples of normal breast tissue, atypical hyperplasia, carcinoma in situ and invasive breast cancer. RT-qPCR was used to detect the expression level of the target miRNAs in serum samples from 24 healthy female subjects, 10 cases breast atypical hyperplasia, 22 cases carcinoma in situ and 40 cases of invasive breast cancer. Results The expression of hsa-miR-486-5P in tissue and serum decreased with the development and progression of breast cancer. It was significantly decline in the serum of early-stage breast cancer patients but had no relationship with breast cancer molecular subtypes ( P＞0. 05 ). The serum expression of hsa-miR-486-5p in early-stage breast cancer patients was significantly lower than that in normal controls ( P＜0.01). The ROC curve analysis showed that the area under the curve was 81.2%(95%CI: 0.707-0.917), the sensitivity and specificity were 62.5%and 90. 3%, respectively. Conclusion Serum hsa-miR-486-5p might be used as a biomarker for the diagnosis of early-stage breast cancer.关键词
hsa-miR-486-5p/miR-486/早期乳腺癌/诊断/非典型增生Key words
hsa-miR-486-5p/miR-486/early-stage breast cancer/diagnosis/atypical hyperplasia分类
医药卫生引用本文复制引用
安学凤,李姝君,俞作仁,韩晶..血清hsa-miR-486-5p在乳腺癌早期诊断中的价值[J].同济大学学报（医学版）,2018,39(3):1-6,6.基金项目
国家自然科学基金面上项目(81572593) （81572593）
